| |
All patients
|
SSRI use
|
|---|
|
Non-user
|
User
|
|---|
|
Number of patients
|
23,669
|
18,885
|
4784
|
|
Year of diagnosis
|
|
1998–2002
|
5738 (24.2%)
|
4491 (23.8%)
|
1247 (26.1%)
|
|
2003–2007
|
8776 (37.1%)
|
6911 (36.6%)
|
1865 (39.0%)
|
|
2008–2012
|
9155 (38.7%)
|
7483 (39.6%)
|
1672 (34.9%)
|
|
Mean age at diagnosis (SD)
|
61.9 (14.0)
|
62.6 (13.9)
|
58.9 (13.9)
|
|
0–49
|
4774 (20.2%)
|
3479 (18.4%)
|
1295 (27.1%)
|
|
50–59
|
5913 (25.0%)
|
4590 (24.3%)
|
1323 (27.7%)
|
|
60–69
|
5955 (25.2%)
|
4903 (26.0%)
|
1052 (22.0%)
|
|
70–79
|
4037 (17.1%)
|
3357 (17.8%)
|
680 (14.2%)
|
|
Deprivation quintile
|
|
1 (least deprived)
|
6026 (25.5%)
|
4923 (26.1%)
|
1103 (23.1%)
|
|
2
|
6087 (25.7%)
|
4923 (26.1%)
|
1164 (24.3%)
|
|
3
|
4873 (20.6%)
|
3875 (20.5%)
|
998 (20.9%)
|
|
4
|
3941 (16.7%)
|
3072 (16.3%)
|
869 (18.2%)
|
|
5 (most deprived)
|
2733 (11.6%)
|
2084 (11.0%)
|
649 (13.6%)
|
|
Missing (n)
|
9
|
8
|
1
|
|
Comorbidities
|
|
Chronic pulmonary disease
|
2716 (11.5%)
|
2033 (10.8%)
|
683 (14.3%)
|
|
Diabetes
|
1456 (6.2%)
|
1141 (6.0%)
|
315 (6.6%)
|
|
Renal disease
|
1076 (4.5%)
|
914 (4.8%)
|
162 (3.4%)
|
|
Cerebrovascular disease
|
650 (2.7%)
|
498 (2.6%)
|
152 (3.2%)
|
|
Congestive heart disease
|
345 (1.5%)
|
287 (1.5%)
|
58 (1.2%)
|
|
Peripheral vascular disease
|
264 (1.1%)
|
211 (1.1%)
|
53 (1.1%)
|
|
Myocardial infarction
|
250 (1.1%)
|
199 (1.1%)
|
51 (1.1%)
|
|
Peptic ulcer disease
|
238 (1.0%)
|
179 (0.9%)
|
59 (1.2%)
|
|
Liver disease
|
45 (0.2%)
|
35 (0.2%)
|
10 (0.2%)
|
|
Hot flushes
|
1693 (7.2%)
|
1024 (5.4%)
|
669 (14.0%)
|
|
Pre-diagnosis confounder medication use
|
|
Hormone replacement therapy
|
7002 (29.6%)
|
5233 (27.7%)
|
1769 (37.0%)
|
|
Oral contraceptive
|
6009 (25.4%)
|
4454 (23.6%)
|
1555 (32.5%)
|
|
Treatment
|
|
Surgery
|
19,218 (81.2%)
|
15,212 (80.6%)
|
4006 (83.7%)
|
|
Tamoxifen
|
10,051 (42.5%)
|
8006 (42.4%)
|
2045 (42.7%)
|
|
Radiotherapy
|
8320 (35.2%)
|
6683 (35.4%)
|
1637 (34.2%)
|
|
Chemotherapy
|
6774 (28.6%)
|
5213 (27.6%)
|
1561 (32.6%)
|
|
Aromatase inhibitors
|
4975 (21.0%)
|
4094 (21.7%)
|
881 (18.4%)
|
|
Grade
|
|
1
|
3780 (17.9%)
|
2988 (17.8%)
|
792 (18.5%)
|
|
2
|
10,282 (48.7%)
|
8210 (48.8%)
|
2072 (48.3%)
|
|
3
|
7039 (33.3%)
|
5616 (33.4%)
|
1423 (33.2%)
|
|
4
|
19 (0.1%)
|
18 (0.1%)
|
1 (0.0%)
|
|
Missing (n)
|
2549
|
2053
|
496
|
|
Stage
|
|
1
|
4791 (49.0%)
|
3812 (48.8%)
|
979 (49.7%)
|
|
2
|
3936 (40.2%)
|
3127 (40.0%)
|
809 (41.1%)
|
|
3
|
748 (7.6%)
|
623 (8.0%)
|
125 (6.4%)
|
|
4
|
309 (3.2%)
|
254 (3.2%)
|
55 (2.8%)
|
|
Missing (n)
|
13,885
|
11,069
|
2816
|
|
Smoking
|
|
No
|
12,975 (61.3%)
|
10,653 (63.4%)
|
2328 (53.2%)
|
|
Ex
|
4677 (22.1%)
|
3696 (22.0%)
|
976 (22.3%)
|
|
Yes
|
3526 (16.6%)
|
2457 (14.6%)
|
1068 (24.4%)
|
|
Missing (n)
|
2491
|
2079
|
412
|
|
Alcohol
|
|
No
|
3406 (19.7%)
|
2711 (19.7%)
|
697 (19.5%)
|
|
Ex
|
347 (2.0%)
|
252 (1.8%)
|
95 (2.7%)
|
|
Yes
|
13,577 (78.3%)
|
10,788 (78.5%)
|
2787 (77.9%)
|
|
Missing (n)
|
6339
|
5134
|
1205
|
|
Obesity
|
|
Normal
|
7723 (41.0%)
|
6178 (41.5%)
|
1548 (39.3%)
|
|
Overweight
|
6326 (33.6%)
|
4999 (33.6%)
|
1325 (33.6%)
|
|
Obese
|
4776 (25.4%)
|
3707 (24.9%)
|
1068 (27.1%)
|
|
Missing (n)
|
4844
|
4001
|
843
|
- Data presented as n (%) unless otherwise indicated
- SSRI selective serotonin reuptake inhibitor, SD standard deviation
